# Phlow awarded US$354M BARDA contract for essential medicines manufacturing

Phlow Corporation received a US$354 million base award from BARDA to manufacture essential medicines at risk of shortage, including for COVID-19. The total contract value is up to US$812 million with options.

- Type: Contract
- Announced: 2020-05-19
- Where: Richmond, Virginia, United States
- Value: $354.0M
- Jobs: 350
- Status: announced
- Products: active pharmaceutical ingredients, finished dosage forms, essential generic medicines
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Phlow Corporation](https://endata.com/companies/47355.md)
- [Biomedical Advanced Research and Development Authority](https://endata.com/companies/8807.md) (customer)
- [U.S. Department of Health and Human Services](https://endata.com/companies/46441.md) (customer)
- [Civica Rx](https://endata.com/companies/47356.md) (partner)
- [Virginia Commonwealth University](https://endata.com/companies/47357.md) (partner)
- [AMPAC Fine Chemicals](https://endata.com/companies/47358.md) (partner)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/phlow-corporation-awarded-354-million-hhsasprbarda-contract-to-manufacture-essential-medicines-in-shortage-301061648.html), 2020-05-19: "Phlow, a U.S.-based, public benefit drug manufacturing corporation, has received federal government funding of $354 million for advanced manufacturing of America's most essential medicines at risk of shortage"
- [upi.com](https://www.upi.com/Top_News/US/2020/05/19/HHS-taps-Virginia-company-to-expand-US-production-of-crucial-drugs/4331589908132/), 2020-05-19: "The COVID-19 pandemic has reminded us how health threats or other sources of instability can threaten America's medical supply chains, potentially endangering Americans' health."
- [phlow-usa.com](https://www.phlow-usa.com/richmond-startup-awarded-354-million-federal-contract-to-make-ingredients-for-covid-19-drugs/), 2020-05-19: "Phlow Corp.'s mission is to provide high-quality, low-cost, essential pharmaceuticals and their key ingredients through state-of-the-art, U.S.-based advanced manufacturing."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.